The company has a registered capital of 20 million yuan and total assets of 654.38+200 million yuan. Its main product, neomycin sulfate, has an annual output of 90 trillion, ranking first in Asia; The annual output of valine is 250 tons; Isoleucine 150 tons, ranking first in China; The annual output of serial amino acid infusion is 20 million bottles, and the annual output of small-volume injections is 654.38+0 billion. Large-capacity injection, neomycin sulfate, amino acid bulk drug, small-capacity injection and veterinary drug successively passed the national GMP certification, and neomycin sulfate passed the FDA certification in 200 1 year1month. Products cover all provinces, municipalities and autonomous regions in China, and are exported to more than 50 countries and regions such as South America, North America, Africa, Europe and Asia. "Three Gorges Brand" series products won the title of "famous brand products" and "high quality products" in Hubei Province in 2002, and enjoyed high popularity at home and abroad. The company has 9 15 employees and 435 professional technicians, accounting for about 40% of the total employees, including more than 0/0 licensed pharmacists. The company has strong technical force, advanced testing methods, attaches great importance to product quality, implements total quality management, and has 60 full-time quality control personnel and product inspection personnel, accounting for 7% of the total number of employees. Equipped with advanced imported inspection instruments such as high performance liquid chromatograph, infrared spectrometer, amino acid automatic analyzer and ultraviolet spectrophotometer, as well as various experimental animals, it can meet the needs of scientific research, production and product inspection of the company. Achieve zero quality defects, and the factory product 100% is qualified. Our company attaches great importance to technological innovation and new product development. It is one of the earliest enterprises in China to research and produce amino acid raw materials by fermentation, and has unique advantages in the research of amino acid derivatives. At present, there are 7 varieties of amino acid raw materials independently developed and more than ten production technologies of amino acid derivatives. The decision of the company's leaders focused on the future, and the land acquisition in Yichang High-tech Industrial Development Zone was 150 mu, and the Three Gorges Pharmaceutical Science and Technology Industrial Park was built with all its efforts, realizing a historic leap in the company's industrial development. The company relies on science and technology for development, adheres to the purpose of quality first and customer first, and establishes a first-class corporate image with first-class service.
June 65438+February 65438+June 2006, Three Gorges Pharmaceutical Group acquired Hubei Zhongtian Aibaike Pharmaceutical Co., Ltd., which was a large-scale comprehensive pharmaceutical industrial enterprise invested by the state in June 1968. Its predecessor was Hubei Pharmaceutical Factory, and now it is a wholly-owned subsidiary of Hubei Zhongtian Group, and it is the well-deserved boss of pharmaceutical production enterprises in our province. However, due to various reasons, the current Hubei Zhongtian Aibaike is unsustainable in terms of funds and personnel, and the historical burden is heavy. After the merger and acquisition of Three Gorges Pharmaceutical Group in June 5438+February 65438+June 2006, the newly established Three Gorges Pharmaceutical Group will have production bases in Yichang and Xiangfan, covering an area of 55 hectares and employing more than 2,000 people, which will nearly double the output of neomycin sulfate of Three Gorges Pharmaceutical Group to more than 2,000 tons, ranking first in the world. At the same time, the GMP drugs produced by the New Three Gorges Pharmaceutical Group will be increased from 3 varieties in the original single series to 8 varieties, and the state-controlled psychotropic and family planning drugs will be added. It is estimated that the annual sales will increase from the current 260 million yuan to 450 million yuan.